HB3666 would require health care professionals in Illinois to report to the Department of Public Health each time they prescribe a puberty blocker to a person under 18. The reports would be submitted quarterly on forms created by the Department, and the forms could not collect identifying information about either the patient or the prescriber. The bill defines puberty blockers as gonadotropin-releasing hormone analogs.
The measure also directs the Department to keep the reports anonymous and confidential, limits access to authorized Department staff for statistical purposes only, and bars the reports from being disclosed under the Freedom of Information Act. It further provides that the reports are not admissible as evidence or discoverable in legal proceedings, and makes a conforming amendment to FOIA to add this new exemption.
Impact
If enacted, HB3666 would add a new reporting requirement to the Department of Public Health Powers and Duties Law and create a new statutory confidentiality exemption in the Freedom of Information Act. It would impose a quarterly administrative reporting obligation on clinicians who prescribe puberty blockers to minors, while also requiring IDPH to design reporting forms and maintain anonymous, nonpublic data for statistical use. The bill would affect health care professionals, the Department of Public Health, and any future access to these records by the public, litigants, or other agencies.
Sentiment
Based on the bill text and the absence of committee testimony or recorded votes, the available record shows no formal legislative sentiment beyond the bill’s introduction. The proposal appears to be framed as a data-collection and confidentiality measure rather than a direct ban or authorization of treatment. Its structure suggests an intent to gather information about pediatric puberty-blocker prescribing while limiting public disclosure and protecting provider and patient anonymity.
Contention
The main point of contention is likely to be the mandatory reporting requirement itself, especially because it targets prescriptions for minors involving gender-affirming care-related medication. Supporters may view the bill as a way to collect statewide statistics and increase oversight, while opponents may argue it singles out a specific treatment, creates administrative burdens, and could chill medical decision-making even with anonymity protections. The confidentiality provisions may reduce privacy concerns, but they do not eliminate broader disputes over whether the state should track these prescriptions at all.
Relative to health care professionals administering hormone treatments and puberty blockers and relative to recognizing the second Thursday in October as children's environmental health day.